Treatment of human immunodeficiency virus during pregnancy: The shift from an exclusive focus on fetal protection to a more balanced approach

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 4, 2000, Pages 856-859

  Kass, Nancy E ^a,b   Taylor, Holly A ^a,b   Anderson, Jean ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ethics; Human immunodeficiency virus; Pregnancy; Teratogens; Zidovudine

Indexed keywords

TERATOGENIC AGENT; ZIDOVUDINE;

CESAREAN SECTION; CONFERENCE PAPER; ETHICS; FETUS DEVELOPMENT; FETUS GROWTH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTHYROIDISM; MATERNAL WELFARE; MEDICAL DECISION MAKING; PREGNANCY; PREGNANCY TERMINATION; PRIORITY JOURNAL; PROTECTION;

EID: 0034058393     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(00)70335-8     Document Type: Article

References (23)

1. 1. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998;338:1128-37.
2. 2. Pitkin RM. Drug treatment of the pregnant women: the state of the art. In: Proceedings of the US Food and Drug Administration Meeting on Regulated Products and Pregnant Women; 1994 Nov 7-8; Crystal City, Virginia.
3. 3. Koren G, Bologa M, Long D, Feldman Y, Shear NH. Perception of teratogenic risk by pregnant women exposed to drugs and chemicals during the first trimester. Am J Obstet Gynecol 1989;160:1190-4.
4. 4. Federal Register, 45 C.F.R. Sect. 46.102(1) (1978).
5. 5. Dept. of Health and Human Services (US). Protection of human subjects; proposed rule. Federal Register 1998;63:27793-804.
6. 6. Kohn N. Neurologic disease. In: Gleicher N, editor. Principles and practices of medical therapy in pregnancy. 3rd ed. Stamford (CT): Appleton & Lange; 1998. p. 1448.
7. 7. Schmidt D, Canger R, Cornaggia C, et al. Seizure frequency during pregnancy and the puerperium: the role of noncompliance and sleep deprivation. In: Porter RJ, Mattson RH, Ward AA, Dam M, editors. Advances in epileptology: Fifteenth Epilepsy International Symposium. New York: Raven Press; 1984. p. 221-5.
8. 8. Kaplan M, Meier D. Thyroid disease in pregnancy. In: Gleicher N, editor. Principles and practices of medical therapy in pregnancy. 3rd ed. Stamford (CT): Appleton & Lange; 1998. p. 432.
9. 9. Davis LE, Lucas MJ, Hankins GDV, et al. Thyrotoxiosis complicating pregnancy. Am J Obstet Gynecol 1989;160:63-70.
10. 10. Dept. of Health and Human Services (US), Public Health Service, Centers for Disease Control and Prevention. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1989;38:1-9.
11. 11. Minkoff H, Moreno J. Drug prophylaxis for human immunodeficiency virus-infected pregnant women: ethical considerations. Am J Obstet Gynecol 1990;163:111-4.
12. 12. Dept. of Health and Human Services (US), Public Health Service, Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1992;41:1-11.
13. 13. Dept. of Health and Human Services (US), Public Health Service, Centers for Disease Control. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus: a summary. MMWR Morb Mortal Wkly Rep 1995;44:1-34.
14. 14. National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service. State-of-the-art conference on azidothymidine virus infection. N Engl J Med 1992;326:2583-9.
15. 15. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR Morb Mortal Wkly Rep 1994;43:285-7.
16. 16. O’Sullivan MJ, Boyer PJJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993;168:1510-6.
17. 17. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996;335:1621-9.
18. 18. Carpenter CCJ, Fischl MA, Hammer SA, et al. Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. JAMA 1996;276:146-54.
19. 19. American College of Obstetricians and Gynecologists. Human immunodeficiency virus infections in pregnancy. Washington: The College; 1997. p. 1-8. Educational Bulletin No.: 232.
20. 20. Dept. of Health and Human Services (US), Public Health Service, Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection. MMWR Morb Mortal Wkly Rep 1998;47:1-82.
21. 21. Dept. of Health and Human Services (US), Public Health Service, Centers for Disease Control and Prevention. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected with HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47:1-36.
22. 22. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updates to recommendations of the International AIDS Society - USA Panel. JAMA 1997; 277:1962-9.
23. 23. Kappy MS. Diabetes in pregnancy: rationale and guidelines for care. Compr Ther 1991;7:50-6.